<DOC>
	<DOCNO>NCT00471445</DOCNO>
	<brief_summary>RATIONALE : Topical cream contain amitriptyline ketamine may help relieve pain , numbness , tingle , symptoms peripheral neuropathy . It yet know whether topical amitriptyline ketamine cream effective placebo treat peripheral neuropathy cause chemotherapy . PURPOSE : This randomized phase III trial study side effect well topical amitriptyline ketamine cream work compare placebo treat peripheral neuropathy cause chemotherapy patient cancer .</brief_summary>
	<brief_title>Topical Amitriptyline Ketamine Cream Treating Peripheral Neuropathy Caused Chemotherapy Cancer Patients</brief_title>
	<detailed_description>OBJECTIVES : - Compare analgesic property safety topical amitriptyline ketamine hydrochloride cream v placebo cancer patient chemotherapy peripheral neuropathy ( CPN ) receive taxanes cancer chemotherapy agent . OUTLINE : This multicenter , double-blind , randomize , placebo-controlled study . Patients stratify accord Community Clinical Oncology Program ( CCOP ) site . Patients randomize 1 2 treatment arm . - Arm I : Patients apply amitriptyline ketamine hydrochloride topical analgesic cream twice daily area pain , numbness , tingle hand and/or foot . - Arm II : Patients apply placebo cream twice daily area pain , numbness , tingle hand and/or foot . In arm , treatment continue 6 week absence disease progression unacceptable toxicity . Patients may continue treatment total 12 week . Patients complete peripheral neuropathy intensity quality sleep diary daily . Patients also complete European Organization Research Treatment Cancer Quality Life-Chemotherapy-Induced Peripheral Neuropathy ( EORTC-CIPN20 ) ass change sensory score Brief Pain Inventory Hospital Anxiety Depression Scale ass health-related quality life week 3 6 . The Vulnerable Elders Survey ( VES-13 ) administer baseline assess level physical activity University Rochester Cancer Center ( URCC ) symptom inventory administer track potentially important symptom . The Patient Global Impression Change Questionnaire administer week 6 ass patient 's overall assessment change since begin treatment , include change pain , side effect , functional status , overall satisfaction treatment . PROJECTED ACCRUAL : A total 462 patient accrue study .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Amitriptyline , perphenazine drug combination</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : History cancer Pain , numbness , tingle hand foot begin association cancer chemotherapy agent ( taxane chemotherapeutic agent ) persist least 28 day follow conclusion chemotherapy Pain , numbness , tingle assess 28 day conclusion chemotherapy An average score ≥ 4 7 daily rating baseline week 11point rating scale peripheral neuropathy associate chemotherapy , minimum 5 daily diary rating complete baseline week No preexist history peripheral neuropathy due cause chemotherapy ( e.g. , hereditary , alcohol , diabetes ) Patients stable systemic metastasis and/or bone involvement AND receive chemotherapy within 3 month screen assessment eligible Patients receive ongoing treatment nonchemotherapy agent ( e.g. , monoclonal antibody hormonal treatment ) allow No concurrent active chemotherapy adjuvant set progressive systemic disease PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Creatinine ≤ 2 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able adequately understand English No allergy hypersensitivity ketamine hydrochloride amitriptyline component study drug No clinically significant illness ( e.g. , endocrine , cardiac , hepatic , renal , neurologic , hematologic , skeletal illness ) , investigator 's clinical judgment , could interfere efficacy safety assessment study No glaucoma recurrent urinary retention No clinically significant depression dementia , opinion investigator , may interfere patient 's adherence study protocol and/or accurate consistent reporting CPN No open skin lesion area cream apply No HIV positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 30 day since prior unapproved experimental drug biological agent No prior topical treatment , nerve block , implantable therapy , peripheral nerve spinal cord stimulation , neurosurgical procedure chemotherapyrelated peripheral neuropathy ( CPN ) No prior exposure peripheral neurotoxin chemotherapy No concurrent medication ( e.g. , phenytoin ) know associated sensory neuropathy No concurrent selective serotonin reuptake inhibitor ( e.g. , fluoxetine , paroxetine , sertraline ) , inhibit CP450 2D6 , unless patient treat depression another psychiatric disorder , investigator 's judgment , patient 's participation study permit give minimal systemic level amitriptyline find within cream No concurrent monoamine oxidase inhibitor , barbiturate , anticholinergic agent , sympathomimetic drug , include epinephrine combine local anesthetic Oral inhaler include drug list allow Concurrent opioid analgesic , tricyclic dual reuptake inhibitor antidepressant , gabapentin pregabalin CPN , benzodiazepines sleep allow , provide dose stable ≥ 2 week follow true : Gabapentin dose ≤ 1,800 mg per day Pregabalin dose ≤ 300 mg per day Opioid analgesic dose ≤ 60 mg oxycodone hydrochloride equivalent per day Tricyclic antidepressant dose ≤ 75 mg amitriptyline equivalent per day Duloxetine dose ≤ 60 mg per day Venlafaxine dose ≤ 150 mg per day Tramadol dose ≤ 200 mg per day Concurrent adjunctive analgesic therapy , acupuncture , biofeedback , herbal preparation , allow provide dose stable ≥ 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>pain</keyword>
	<keyword>neurotoxicity</keyword>
	<keyword>peripheral neuropathy</keyword>
</DOC>